PPARG and type 2 diabetes mellitus: PPARγ agonists attenuate nephropathy in experimental models of anti-GBM-GN [31], lupus erythematosus, type 2 diabetes, and non-diabetic glomerulosclerosis, and decrease proteinuria in patients with type 2 diabetes and non-diabetic renal disease [32–35].